Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mrinalini Dey, Sizheng Steven Zhao & Robert J. Moots. (2021) Anti-TNF biosimilars in rheumatology: the end of an era?. Expert Opinion on Biological Therapy 21:1, pages 29-36.
Read now
Read now
András Harsányi, Marcell Csanádi, Kristóf Márky, Áron Zoltán Vincziczki, Zoltán Kaló & András Inotai. (2020) Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. Expert Review of Pharmacoeconomics & Outcomes Research 20:6, pages 653-659.
Read now
Read now
András Inotai & Zoltán Kaló. (2019) How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 627-632.
Read now
Read now
Christopher J. Edwards, Jana Hercogová, Helene Albrand & Aurelian Amiot. (2019) Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opinion on Biological Therapy 19:10, pages 1001-1014.
Read now
Read now
András Inotai, Tamás Ágh, Alexei Willem Karpenko, Antal Zemplényi & Zoltán Kaló. (2019) Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research 19:2, pages 105-113.
Read now
Read now
Articles from other publishers (22)
Zornitsa Mitkova, Ivan Manev, Konstantin Tachkov, Vladimira Boyadzhieva, Nikolay Stoilov, Miglena Doneva & Guenka Petrova. (2023) How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example. Healthcare 11:17, pages 2427.
Crossref
Crossref
Juan M. Reyes, Magda V. Gutierrez‐Ardila, Hugo Madariaga, William Otero, Renato Guzman, Jorge Izquierdo, David J. Del Castillo, Mauricio Abello, Patricia Velez, Dario Ponce de Leon, Tatjana Lukic, Luisa F. Amador & Natalia Castaño. (2023) Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study. Health Science Reports 6:3.
Crossref
Crossref
Philip G Conaghan, Karel Pavelka, Song-Chou Hsieh, Terri-Leigh Bonnington, Toby C Kent, Katie Marchbank & Christopher J Edwards. (2023) Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials. Rheumatology Advances in Practice 7:1.
Crossref
Crossref
Bernard Combe, Robin Besuyen, Antonio Gómez-Centeno, Tsukasa Matsubara, Juan José Sancho Jimenez, Zhaoyu Yin & Maya H. Buch. (2022) Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatology and Therapy.
Crossref
Crossref
Manuel Enrique Machado-Duque, Andrés Gaviria-Mendoza, Juan Camilo Toro-Jiménez, Santiago Cano-Marín, Lorena Osorio-Gutiérrez, Luis Felipe Hernández-Cano & Jorge Enrique Machado-Alba. (2022) Efectividad y seguridad en el manejo de enfermedades inflamatorias crónicas con medicamentos biosimilares de etanercept e infliximab en pacientes colombianos. Revista Colombiana de Reumatología 29:4, pages 256-264.
Crossref
Crossref
Min Jung Kim, Eun Hye Park, Anna Shin, You-Jung Ha, Yun Jong Lee, Eun Bong Lee, Han Joo Baek & Eun Ha Kang. (2022) Assessment on Treatments With Conventional Synthetic Disease-modifying Drugs Before Initiating Biologics in Patients With Rheumatoid Arthritis in Korea: A Population-based Study. Journal of Rheumatic Diseases 29:2, pages 79-88.
Crossref
Crossref
Frank McKenna. (2022) Treatment of moderate rheumatoid arthritis. Rheumatology 61:2, pages 478-479.
Crossref
Crossref
Eunyoung Emily Lee, Anna Shin, Joongyub Lee, Joo Ho Lee, You-Jung Ha, Yun Jong Lee, Eun Bong Lee, Yeong Wook Song & Eun Ha Kang. (2022) All-cause and cause-specific mortality of patients with rheumatoid arthritis in Korea: A nation-wide population-based study. Joint Bone Spine 89:1, pages 105269.
Crossref
Crossref
Arvind Kaul, Jatin Mistry, Annamaria Iagnocco, Xenofon Baraliakos, Ailsa Bosworth & Iain McNicol. (2021) Inequality of access to advanced therapies for patients with inflammatory arthritis: a postcode lottery?. Rheumatology Advances in Practice 5:3.
Crossref
Crossref
Krzysztof Bonek, Leszek Roszkowski, Magdalena Massalska, Wlodzimierz Maslinski & Marzena Ciechomska. (2021) Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Cells 10:2, pages 323.
Crossref
Crossref
Mourad F. Rezk & Burkhard Pieper. (2020) Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. Advances in Therapy 37:9, pages 3732-3745.
Crossref
Crossref
Yunkyung Kim, Geun-Tae Kim, Young Sun Suh, Hyun-Ok Kim, Han-Na Lee & Seung-Geun Lee. (2020)
The Impact of the Amendment of the Korean National Health Insurance Reimbursement Criteria for Anti-tumor Necrosis Factor-
α
Agents on Treatment Pattern, Clinical Response and Persistence in Patients With Rheumatoid Arthritis
. Journal of Rheumatic Diseases 27:3, pages 159-167.
Crossref
Crossref
András Inotai, Dominik Tomek, Maciej Niewada, László Lorenzovici, Martin Kolek, Jakub Weber, Anne-Katrin Kurrat, Emese Virág Kiss & Zoltán Kaló. (2020) Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries. Frontiers in Pharmacology 11.
Crossref
Crossref
Stanley B. Cohen, Sebastiao C. Radominski, Hideto Kameda, Alan J. Kivitz, Michael Tee, Carol Cronenberger, Min Zhang, Sarah Hackley, Muhammad I. Rehman, Oliver von Richter & Rieke Alten. (2020) Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial. BioDrugs 34:2, pages 197-207.
Crossref
Crossref
J. Hercogová, K.A. Papp, V. Chyrok, M. Ullmann, P. Vlachos & C.J. Edwards. (2019)
AURIEL
‐PsO: a randomized, double‐blind phase
III
equivalence trial to demonstrate the clinical similarity of the proposed biosimilar
MSB
11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
. British Journal of Dermatology 182:2, pages 316-326.
Crossref
Crossref
HoUng Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jørgen Jahnsen, Péter L. Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese & Ji Hoon Jeong. (2020) The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 80:2, pages 99-113.
Crossref
Crossref
Hans C. Ebbers, Burkhard Pieper, Amine Issa, Janet Addison, Ulrich Freudensprung & Mourad F. Rezk. (2019) Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review. Rheumatology and Therapy 6:3, pages 317-338.
Crossref
Crossref
Bogdan Batko, Karol Urbański, Jerzy Świerkot, Piotr Wiland, Filip Raciborski, Mariusz Jędrzejewski, Mateusz Koziej, Marta Cześnikiewicz-Guzik, Tomasz J. Guzik & Marcin Stajszczyk. (2019) Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. Clinical Rheumatology 38:9, pages 2473-2481.
Crossref
Crossref
Olga Löblová, Marcell Csanádi, Piotr Ozierański, Zoltán Kaló, Lawrence King & Martin McKee. (2019) Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology. Health Policy 123:7, pages 630-634.
Crossref
Crossref
Daniel C. Baumgart, Laurent Misery, Sue Naeyaert & Peter C. Taylor. (2019) Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology 10.
Crossref
Crossref
Stanley B. Cohen, Rieke Alten, Hideto Kameda, Tomas Hala, Sebastiao C. Radominski, Muhammad I. Rehman, Ramesh Palaparthy, Karl Schumacher, Susanne Schmitt, Steven Y. Hua, Claudia Ianos & K. Lea Sewell. (2018) A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Research & Therapy 20:1.
Crossref
Crossref
Andras Inotai, Marcell Csanadi, Guenka Petrova, Maria Dimitrova, Tomasz Bochenek, Tomas Tesar, Kristina York, Leos Fuksa, Alexander Kostyuk, Laszlo Lorenzovici, Vitaly Omelyanovskiy, Katalin Egyed & Zoltan Kalo. (2018) Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed Research International 2018, pages 1-9.
Crossref
Crossref